KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Non-Current Deffered Revenue (2016 - 2022)

Inovio Pharmaceuticals' Non-Current Deffered Revenue history spans 13 years, with the latest figure at $56935.0 for Q2 2022.

  • For Q2 2022, Non-Current Deffered Revenue fell 20.69% year-over-year to $56935.0; the TTM value through Jun 2022 reached $56935.0, down 20.69%, while the annual FY2021 figure was $64361.0, 18.75% down from the prior year.
  • Non-Current Deffered Revenue for Q2 2022 was $56935.0 at Inovio Pharmaceuticals, down from $60648.0 in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $203322.0 in Q1 2018 and bottomed at $56935.0 in Q2 2022.
  • The 5-year median for Non-Current Deffered Revenue is $86641.0 (2020), against an average of $106473.6.
  • The largest YoY upside for Non-Current Deffered Revenue was 10.62% in 2018 against a maximum downside of 97.68% in 2018.
  • A 5-year view of Non-Current Deffered Revenue shows it stood at $150793.0 in 2018, then tumbled by 32.64% to $101567.0 in 2019, then dropped by 22.01% to $79214.0 in 2020, then decreased by 18.75% to $64361.0 in 2021, then fell by 11.54% to $56935.0 in 2022.
  • Per Business Quant, the three most recent readings for INO's Non-Current Deffered Revenue are $56935.0 (Q2 2022), $60648.0 (Q1 2022), and $64361.0 (Q4 2021).